Ultragenyx Pharmaceutical (RARE) stock is in focus as the company completes FDA rolling submission for FDA approval of its ...

According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...

X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...

Satyen K. Bordoloi My first memory of cancer is the younger brother of a classmate. Blood cancer, we whispered between ...

Authors explore complexities in scaling gene-therapy production with special attention is to monitoring and enhancing ...

Minaris will move its center for viral vector innovation to occupy space within CGT Catapult's collaborator laboratories in London and will work with CGT Catapult on the further development of ...

Nonprofit founder and CEO, Craig Martin, notes that the industry will likely see more alternative gene therapy commercialisation models in the future.

The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular atrophy (SMA) ...

The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that ...

Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled "Efficient LAMA1 gene ...

Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts ...

The treatment uses a modified, harmless virus to deliver healthy genes to a patient’s cells to treat genetic diseases. Read more at straitstimes.com. Read more at straitstimes.com.